396 related articles for article (PubMed ID: 33675775)
1. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
2. The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.
Attia YM; Tawfiq RA; Ali AA; Elmazar MM
Sci Rep; 2017 Oct; 7(1):12502. PubMed ID: 28970500
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene.
Li S; Xu Z; Guo J; Zheng J; Sun X; Yu J
J Cell Mol Med; 2020 Dec; 24(24):14549-14560. PubMed ID: 33164339
[TBL] [Abstract][Full Text] [Related]
4. FXR induces SOCS3 and suppresses hepatocellular carcinoma.
Guo F; Xu Z; Zhang Y; Jiang P; Huang G; Chen S; Lyu X; Zheng P; Zhao X; Zeng Y; Wang S; He F
Oncotarget; 2015 Oct; 6(33):34606-16. PubMed ID: 26416445
[TBL] [Abstract][Full Text] [Related]
5. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
6. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
8. FXR ligands protect against hepatocellular inflammation via SOCS3 induction.
Xu Z; Huang G; Gong W; Zhou P; Zhao Y; Zhang Y; Zeng Y; Gao M; Pan Z; He F
Cell Signal; 2012 Aug; 24(8):1658-64. PubMed ID: 22560881
[TBL] [Abstract][Full Text] [Related]
9. MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.
Xiao Y; Li Y; Shi D; Wang X; Dai S; Yang M; Kong L; Chen B; Huang X; Lin C; Liao W; Xu B; Chen X; Wang L; Chen X; Ouyang Y; Liu G; Li H; Song L
Cancer Res; 2022 Nov; 82(22):4191-4205. PubMed ID: 36112698
[TBL] [Abstract][Full Text] [Related]
10. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
11. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
14. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
15. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production.
Ogata H; Chinen T; Yoshida T; Kinjyo I; Takaesu G; Shiraishi H; Iida M; Kobayashi T; Yoshimura A
Oncogene; 2006 Apr; 25(17):2520-30. PubMed ID: 16474852
[TBL] [Abstract][Full Text] [Related]
16. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma.
Jiang LH; Hao YL; Zhu JW
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):282-291. PubMed ID: 30385249
[TBL] [Abstract][Full Text] [Related]
18. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
19. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
[TBL] [Abstract][Full Text] [Related]
20. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells.
Wonganan O; He YJ; Shen XF; Wongkrajang K; Suksamrarn A; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2017 Dec; 336():31-39. PubMed ID: 29031523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
